With an “interesting” new development recently introduced by the Lotus team, part 3 in the series looks at what effect the new system may have in the second half of the season. In first practice of ...
A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results